Advertisement
Advertisement
April 19, 2010
Trial Begins for AngioDynamics NanoKnife IRE System to Treat Early-Stage Liver Cancer
April 20, 2010—AngioDynamics, Inc. (Queensbury, NY) announced that the first patient was treated in a pilot study of the company's NanoKnife irreversible electroporation (IRE) system to treat early-stage hepatocellular carcinoma. The purpose of the prospective multicenter trial is to study the safety and efficacy of IRE in treating early-stage liver cancer. It is being conducted under the supervision of Professor Jordi Bruix, MD, from the University of Barcelona and Professor Riccardo Lencioni, MD, from the University of Pisa. Patient enrollment is underway in Pisa, and the trial has been initiated at two medical centers in Germany and one in Spain. The company expects that seven centers will participate in the study. As of March 31, 2010, physicians have treated a total of 154 patients at 11 centers around the world using the NanoKnife IRE system for procedures performed on prostates, livers, lungs, and pancreata, the company stated.
Advertisement
Advertisement
